atorvastatin has been researched along with Diabetes Mellitus, Adult-Onset in 338 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (0.89) | 18.2507 |
| 2000's | 168 (49.70) | 29.6817 |
| 2010's | 134 (39.64) | 24.3611 |
| 2020's | 33 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Mu, T; Shao, Q; Tong, N; Yang, X; Zhang, X; Zhang, Y; Zhou, Y | 1 |
| Bozkurt, I; Feyizoglu, G; Gul, Z; Karsli, A; Oguz, A; Telci Caklili, O; Vural Keskinler, M | 1 |
| Borowska, M; Domagała, J; Dworacka, M; Dworacki, G; Iskakova, S; Mikołajczak, PŁ; Owoc, J; Wesołowska, A; Winiarska, H | 1 |
| El Medany, AMH; Ghazala, RA; Hammadi, SHM; Khalifa, HM; Zakaria Mohammed, HS | 1 |
| Bjourson, AJ; English, AR; Horigan, G; Kelly, C; McClean, PL; McGuigan, DH; O'Kane, M; Prasad, B; Shukla, P | 1 |
| Jameshorani, M; Mellati, AA; Mousavi, SN; Rahimian, A; Rostamkhani, H; Tabaei, BS | 1 |
| Li, L; Sun, Q; Zhou, Q | 1 |
| Kristensen, K; Langeskov, EK | 1 |
| Borghi, C; Cicero, AFG; D'Addato, S; Fogacci, F; Giovannini, M; Rizzoli, E | 1 |
| Anghel, R; Forsea, L; Gales, L; Georgescu, M; Mitrea, D; Mitrica, R; Serbanescu, L; Stanculescu, I; Stefanica, I; Trifanescu, O | 1 |
| Chen, M; Li, M; Liu, S; Ma, F; Su, B; Wang, C; Yuan, L; Zhang, S; Zhang, Y; Zheng, Q | 1 |
| Avram, C; Baba, DF; Danilesco, A; Huma, L; Moldovan, DA; Rauta, RC; Sin, IA; Suciu, H | 1 |
| Susekov, AV | 1 |
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 1 |
| Farooq Ur Rehman, RM; Khokhar, SA; Masood, S | 1 |
| Abid, L; Ayedi, F; Bahloul, A; Ben Mrad, I; Charfeddine, S; Charfi, R; Ellouze, T; Gargouri, R; Hammami, R; Jdidi, J; Kammoun, S; Masmoudi, O; Turki, M | 1 |
| Hu, WS; Lin, CL; Yu, TS | 1 |
| Chen, WM; Chiang, MF; Lee, MC; Lo, HC; Soong, RS; Wu, MS; Wu, SY | 1 |
| Du, M; Wang, Q; Wang, T; Zhu, S | 1 |
| Namazova, GA; Shupenina, EY; Vasyuk, YA; Zavyalova, AI | 1 |
| Dos Anjos, PMF; Miranda, TC; Nogueira-Machado, JA; Volpe, CMO | 1 |
| Cummings, JL; Ginsberg, HD; Johansson, JO; Kalantar-Zadeh, K; Kulikowski, E; Nicholls, SJ; Ray, KK; Schwartz, GG; Sweeney, M; Toth, PP; Wong, N | 1 |
| Drews, G; Düfer, M; Hoffmeister, T; Kaiser, J; Lüdtke, S | 1 |
| Bawden, D; Dhatariya, KK; Gaur, S | 1 |
| Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Miyazaki, T; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Abdullah, S; Abed, E; Alhawari, H; Jarrar, Y; Zihlif, M | 1 |
| Dakin, HA; Farmer, A; Gray, AM; Holman, RR | 1 |
| Lao, VWN; Lau, WY; Lee, KF; Mak, MWH; Wong, VTL; Yip, HLK | 1 |
| Cao, X; Chen, Y; Huang, X; Li, Y; Wu, L; Xiao, H; Zhou, X | 1 |
| Khairat, I; Khedr, NF; Werida, R | 1 |
| Hüttl, M; Kazdová, L; Malínská, H; Marková, I; Miklánková, D; Oliyarnyk, O; Poruba, M; Rácová, Z; Večeřa, R | 1 |
| Awortwe, C; Joubert, E; Louw, J; Muller, CJF; Patel, O; Rosenkranz, B | 1 |
| Iimuro, S; Matsuyama, Y; Shinozaki, T; Yamamuro, S | 1 |
| Handayani, W; Yogiarto, M | 1 |
| Genser, B; März, W; Wanner, C | 1 |
| Kochubiei, O; Ovrakh, T; Serik, S | 1 |
| Ai, XB; Li, L; Wang, F; Wang, J; Yi, XL; Zou, YW | 1 |
| Chen, W; Sun, Z; Tian, T; Wang, S; Xue, Y | 1 |
| Jannowitz, C; Laufs, U; Pittrow, D | 1 |
| Mikhailidis, DP; Paraskevas, KI | 1 |
| Anil, C; Bozkus, Y; Demir, C; Kut, A; Mousa, U; Nar, A; Tutuncu, NB | 1 |
| Cervantes-Flores, M; Delgado-León, TG; López-Guzmán, OD; Lozano-Guzmán, E; Martínez-Romero, A; Sálas-Pacheco, JM; Úrtiz-Estrada, N; Vazquez-Alaniz, F; Vértiz-Hernández, ÁA | 1 |
| Aguilar Salinas, CA; Brito-Córdova, G; Chapman, MJ; Dauteuille, C; Kontush, A; Lesnik, P; Lhomme, M; Lozano-Arvizu, F; Muñoz-Hernandez, L; Ortiz-Bautista, RJ; Pérez-Méndez, O; Saucedo, S; Zentella-Dehesa, A | 1 |
| de Zeeuw, D; Heerspink, HJL; Idzerda, NMA; Parving, HH; Pena, MJ | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Sykara, M; Tentolouris, A; Tentolouris, N; Tsilingiris, D; Vlachopoulos, C | 1 |
| Fang, H; Hu, J; Li, M | 1 |
| Antova, E; Bosevska, G; Bosevski, M; Krstevski, G; Mitevska, I | 1 |
| Huang, Z; Li, Q; Li, X; Ye, W; Zhang, Q | 1 |
| Gonzalo-Martinez, JF; Herrero-San Martin, A; Ostos-Moliz, F; Sanchez-Tejerina San Jose, D; Toldos-Gonzalez, O | 1 |
| Bochar, O; Bondarenko, O; Karpyshyn, N; Maksymets, T; Sklyarov, Y; Sorochka, M | 1 |
| Bahrey, D; Demoz, GT; Hagazy, K; Kasahun, GG; Kinfe, DG; Niriayo, YL; Tasew, H; Wahdey, S | 1 |
| Bass, R; Dishy, V; Furuie, H; Ishizuka, H; Kamiyama, E; Kato, M; Maekawa, Y; Myobatake, Y; Shiosakai, K; Taguchi, T; Vashi, V; Warren, V; Watanabe, A; Zhou, J | 1 |
| Hirayama, A; Hiro, T; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Filipiak, KJ; Mamcarz, A; Naruszewicz, M; Siebert, J; Sliż, D | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Kang, HJ; Kim, HS; Lee, JH; Oh, BH; Park, YB; Sohn, DW | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Chen, JW; Chen, JY; Chien, KL; Hsia, CH; Hung, YR; Lin, HJ; Lin, LY; Liu, PY; Wu, TC; Yeh, HI | 1 |
| Bhansali, A; Jani, RH; Jariwala, G; Jha, P; Joshi, S; Mukhopadhyay, S; Pai, V | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C | 1 |
| Bech, JN; Hansen, AB; Jensen, JM; Larsen, T; Mose, FH; Pedersen, EB | 1 |
| Louro, T; Matafome, P; Nunes, E; Seiça, RM; Sena, CM | 1 |
| Bogucki, J; Feldo, J; Feldo, M; Kęsik, J; Kocki, J; Lukasik, S; Terlecki, P; Wroński, J; Zubilewicz, T | 1 |
| Fotiadis, G; Kadoglou, NP; Kapelouzou, A; Liapis, CD; Sailer, N | 1 |
| Amato, AA; Puig, A; Scripko, PD | 1 |
| Aslam, M; Bhattacharya, SK; Galav, V; Jafri, AA; Madhu, SV | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T | 4 |
| Bao, W; Betteridge, DJ; Buchan, AP; Colhoun, H; DeMicco, DA; Durrington, PN; Fuller, JH; Hawa, MI; Hitman, GA; Leslie, RD; Neil, HA; Ola, T; Wun, CC | 1 |
| Chang, YH; Lee, YJ; Lin, KD; Shin, SJ | 1 |
| Goyal, A; Gupta, N; Gupta, YK; Singh, S; Tandon, N | 1 |
| Al-Azzam, SI; Alzayadeen, RN; Alzoubi, KH; Khabour, OF | 1 |
| Chang, TT; Chen, JS; Chen, JW; Huang, CC; Huang, PH; Leu, HB; Lin, LY; Lin, SJ; Wu, TC | 1 |
| Carlson, J | 1 |
| Chi, J; Guo, L; Jiang, L; Li, H; Li, M; Pan, Q; Sun, M; Wang, X; Wang, Y; Xian, T; Yu, D | 1 |
| Antunes, TT; Bruder-Nascimento, T; Callera, GE; He, Y; Montezano, AC; Nguyen Dinh Cat, A; Tostes, RC; Touyz, RM | 1 |
| Drechsler, C; Genser, B; Hengstschläger, M; Kaltenecker, CC; Kopecky, C; Krane, V; März, W; Säemann, MD; Wanner, C; Weichhart, T | 1 |
| Chan, KA; Chou, HW; Lai, CL; Lai, MS | 1 |
| Betteridge, J; Bittner, VA; Fayyad, R; Hsue, PY; Laskey, R; Waters, DD; Wenger, NK | 1 |
| Frölich, JC; Huisman, MV; Pham, VV; Princen, HM; Suchy, MT; Tsikas, D; van de Ree, MA | 1 |
| Berg, AH; Drechsler, C; Hod, T; Kalim, S; Karumanchi, SA; Suntharalingam, P; Thadhani, RI; Wanner, C; Wenger, JB | 1 |
| Corbalan, JJ; Dawoud, H; Jacob, RF; Malinski, T; Mason, RP | 1 |
| Kumar, V; Singh, A; Singh, BK | 1 |
| Li, L; Li, Y; Shen, J; Shen, Y; Su, F; Zhang, D; Zhang, M | 1 |
| Bao, W; Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA; Preston, GM; Schalkwijk, CG; Soedamah-Muthu, SS; Stehouwer, CD | 1 |
| Hieshima, K; Jinnouchi, H; Jinnouchi, T; Kajiwara, K; Kurinami, N; Matsui, K; Miyamoto, F; Sugiyama, S; Suzuki, T | 1 |
| Raj, DS; Ramezani, A; Velasquez, MT | 1 |
| Agha, A; Ashley, DT; Davenport, C; McHenry, CM; O'Gorman, DJ; O'Sullivan, EP; Smith, D; Thompson, CJ | 1 |
| Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W | 1 |
| Capel, F; Chabrier, G; Cynober, L; de Bandt, JP; Durand, C; Jouve, C; Le Plenier, S; Moinard, C; Morio, B; Pitois, E; Rigaudière, JP | 1 |
| Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV | 1 |
| Ambery, P; Atkinson, G; Baylor Curtis, L; Dott, C; Haque, N; LaCroix, K; Min, KW; Stylianou, A | 1 |
| Fan, Y; Fang, N; Gong, D; Han, W | 1 |
| Akbar, T; Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Looker, HC; Neil, HA | 1 |
| Bando, Y; Hisada, A; Kanehara, H; Okafuji, K; Tanaka, N; Toya, D; Toyama, H | 1 |
| Dieplinger, H; Drechsler, C; Kollerits, B; Krane, V; Kronenberg, F; Lamina, C; März, W; Ritz, E; Wanner, C | 1 |
| Aggarwal, S; Aslam, M; Galav, V; Madhu, SV; Sharma, KK | 1 |
| Gutjahr-Lengsfeld, LJ; Krane, V; Mann, JF; März, W; Schmidt, KR; Swoboda, F; Wanner, C | 1 |
| Alizadeh, A; Kashi, Z; Kianmehr, A; Mahrooz, A | 1 |
| Boekholdt, SM; Colhoun, HM; Davis, BR; Kaasenbrood, L; Livingstone, SJ; Poulter, NR; Pressel, SL; Sever, PS; van der Graaf, Y; Visseren, FL | 1 |
| Arsenault, BJ; DeMicco, DA; Kastelein, JJ; Kohli, P; Lambert, G; Laskey, R; Messig, MM; Waters, DD | 1 |
| Kumari, M; Martande, SS; Naik, SB; Pradeep, AR | 1 |
| Hao, H; Li, J; Liu, Z; Wang, Y; Xu, D; Xu, J; Xu, Y; Yin, C | 1 |
| Farmer, AJ; Griffin, S; Hardeman, W; Holman, RR; Kinmonth, AL; Oke, J; Sutton, S; Tucker, L | 1 |
| Bob, F; Dumitrascu, V; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Jianu, DC; Matusz, P; Petrica, L; Popescu, R; Secara, A; Simulescu, A; Ursoniu, S; Velciov, S; Vlad, A; Vlad, D; Vlad, M | 1 |
| Barwari, T; Bonora, E; Fernández-Hernando, C; Goedeke, L; Hughes, AD; Kaudewitz, D; Kiechl, S; Mayr, M; Moschen, AR; Ramírez, CM; Rotllan, N; Santer, P; Skroblin, P; Tilg, H; Whitehead, M; Willeit, J; Willeit, P; Yin, X; Zampetaki, A | 1 |
| Bründler, J; Oestmann, A; Repond, F | 1 |
| Chandra, N; Mateen, AA; Naidu, MU; Raju, YS; Usharani, P | 1 |
| Albalat-Galera, R; Berzosa-Sanchez, M; Ferrer-García, JC; Herrera-Ballester, A; Sanchez-Ballester, E | 1 |
| Bittner, VA; Breazna, A; Carmena, R; Deedwania, PC; Dobson, S; Kastelein, JP; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, AL | 1 |
| Auster, S; Betteridge, DJ; Colhoun, HM; Demicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Neil, HA; Newman, CB; Szarek, M | 1 |
| Baumann, M; Bierhaus, A; Bluemm, A; Dugi, KA; Heemann, U; Humpert, PM; Liu, D; Lutz, J; Nawroth, PP; Schuster, T; von Eynatten, M | 1 |
| Kékes, E | 1 |
| Drechsler, C; Krane, V; Lilienthal, J; März, W; Wanner, C; Winkler, K | 2 |
| de Teresa, E; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martineau, P | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Moedas, AR; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, H; DeMicco, DA; Durrington, PN; France, M; Fuller, J; Hitman, GA; Livingstone, SJ; Neil, HA; Newman, CB; Szarek, M | 2 |
| Balasubramanian, R; Baliga, VP; Bolmall, C; Kathale, A; Nagraj, LM; Nayak, UP; Periyandavar, I; Sharma, A; Varadharajan, S | 1 |
| Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T | 1 |
| Farmer, A; Holman, RR; Neil, HA; Paul, S; Stratton, IM; Tucker, L | 1 |
| Amudha, K; Choy, AM; Lang, CC; Mustafa, MR | 1 |
| Channer, KS; Jones, TH; Kapoor, D; Stanworth, RD | 1 |
| Sniderman, A; Solhpour, A | 1 |
| Angermann, C; Bauersachs, J; Frantz, S; Heinrich, F; Krane, V; Lilienthal, J; Meesmann, M; Olschewski, M; Störk, S; Wanner, C | 1 |
| Dallinga-Thie, GM; Jansen, H; Kastelein, JJ; Sijbrands, EJ; van Hoek, M; van Tol, A; van Vark-van der Zee, LC | 1 |
| Blanco-Colio, LM; de Teresa, E; Dilaghi, B; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gori, AM; Langer, A; Leiter, LA; Martineau, P; Nozza, A; Rostagno, C | 1 |
| Glinkina, IV; Il'in, AV; Mel'nichenko, GA; Roĭtman, AP; Zilov, AV | 1 |
| Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karti, SS; Ukinc, K | 1 |
| Dallinga-Thie, GM; Dullaart, RP; van Tol, A | 1 |
| Giraudeaux, V; Guillausseau, PJ; Kévorkian, JP; Laloi-Michelin, M; Meas, T; Peynet, J; Virally, M | 1 |
| Chowdhury, S; Mukherjee, S; Mukhopadhyay, P; Pandit, K | 1 |
| El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Frye, RF; Johnson, MH; Kozak, A | 1 |
| Banga, JD; Dallinga-Thie, GM; Dullaart, RP; Huisman, MV; Kappelle, PJ; Sluiter, WJ; Zwang, L | 1 |
| Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA | 1 |
| Saito, Y; Yokote, K | 1 |
| Das, R; Jaydip, R; Mohan, V; Sudhakaran, C; Unnikrishnan, R | 1 |
| Betteridge, DJ; Chow, WS; Shiu, SW; Tam, HL; Tan, KC; Wong, Y | 1 |
| Altuntas, Y; Arinc, H; Bolayirli, M; Celebi, H; Dirican, A; Kanat, M; Karagoz, Y; Oguz, A; Sahin, S; Serin, E; Tunckale, A; Yildiz, O | 1 |
| Bi, S; Li, J; Li, YB; Liu, GD; Liu, XM; Su, Y; Sun, YM; Xu, Y | 1 |
| Dallinga-Thie, GM; Dullaart, RP; Kappelle, PJ | 1 |
| Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K | 1 |
| Kuriyama, G; Mori, Y; Tajima, N; Tanaka, T | 1 |
| Antoniades, C; Charakida, M; Kamboli, AM; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Siasos, G; Stefanadi, E; Stefanadis, C; Tousoulis, D | 1 |
| Bech, JN; Matthesen, SK; Paulsen, L; Pedersen, EB; Starklint, J | 1 |
| Annemans, L; Marbaix, S; Scheen, A; Van Gaal, L; Webb, K | 1 |
| Buchetti, B; Carnovale, A; Fallarino, M; Filetti, S; Gatti, A; Lenti, L; Lococo, E; Mandosi, E; Morano, S; Rossetti, M | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Goldberg, RB; Guyton, JR; Mazzone, T; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE; Weinstock, RS | 1 |
| Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K | 1 |
| Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R | 1 |
| Tuttle, KR | 1 |
| Harinarayan, CV; Kumar, R; Pola, P; Rajagopal, G; Reddy, AP; Sachan, A; Suchitra, MM; Suresh, V | 1 |
| Cariou, B; Costet, P; Guyomarc'h Delasalle, B; Hoffmann, MM; Konrad, T; Winkler, K | 1 |
| Abdel-Salam, Z; Adel, A; Nammas, W | 1 |
| Ceglarek, U; Farmer, A; Holman, RR; Neil, HA; Paul, S; Thiery, J | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Bando, YK; Monji, A; Morimoto, Y; Murohara, T; Shigeta, T | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Charlton-Menys, V; Cruickshank, JK; Davies, RR; Dean, J; Durrington, PN; France, M; Gibson, JM; Gittins, M; Jinadev, P; Kalra, PA; Moorhouse, A; Prais, HR; Roberts, C; Rutter, MK; Wiles, PG | 1 |
| Antoniades, C; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Stefanadi, E; Stefanadis, C; Tousoulis, D | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Higa, M; Masuzaki, H; Shimabukuro, M; Shimabukuro, T; Tanaka, H; Yamakawa, K | 1 |
| Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T | 1 |
| Allolio, B; Blouin, K; Drechsler, C; Fenske, W; Krane, V; Lilienthal, J; Wanner, C | 1 |
| Bancells, C; Benítez, S; Ordóñez-Llanos, J; Pérez, A; Sánchez-Quesada, JL; Wägner, AM | 1 |
| Arsenault, BJ; Barter, P; Breazna, A; Colhoun, H; DeMicco, DA; Ho, JE; Kastelein, JJ; Waters, DD; Wun, CC | 1 |
| Drechsler, C; Genser, B; Grammer, TB; Holdaas, H; Holme, I; Krane, V; März, W; Ritz, E; Scharnagl, H; Stojakovic, T; Wanner, C; Winkler, K | 1 |
| John, H; Kitas, GD; Toms, TE | 1 |
| Eeg-Olofsson, K; Eliasson, B; Gudbjörnsdóttir, S; Jonasson, JM; Miftaraj, M; Sundell, KA; Svensson, AM | 1 |
| Eren, MA; Koksal, M; Sabuncu, T; Turan, MN | 1 |
| Altafullah, I; Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Ledbetter, LY; MacLeod, MJ; Messig, M; Samsa, GP; Scott, R; Sillesen, H; Welch, KM; Zivin, JA | 1 |
| Ahmed, D; Pillai, KK; Sharma, M | 1 |
| Fagan, SC; Guan, W; Kozak, A | 1 |
| Kadoglou, NP; Kapelouzou, A; Kostakis, A; Lampropoulos, S; Liapis, CD; Sailer, N; Vitta, I | 1 |
| Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD | 1 |
| Budinski, D; Gosho, M; Gumprecht, J; Hounslow, N | 1 |
| Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C | 1 |
| Arora, R; Dey, S; Kandhwal, K; Monif, T; Nazarudheen, S; Rao, S; Reyar, S; Singh, MK; Thudi, NR | 1 |
| Tanaka, M | 1 |
| Fraser, H; Goulder, MA; Hislop, C; Rosenson, RS | 1 |
| Ishii, H; Koyasu, M; Matsubara, T; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M; Yoshikawa, D | 1 |
| Schalkwijk, CG; Simsek, S; Wolffenbuttel, BH | 1 |
| Teramoto, T | 1 |
| Drechsler, C; Hoffmann, MM; Krane, V; Wanner, C; Winkler, K | 1 |
| Betteridge, DJ; Calle, RA; Caulfield, M; Charlton-Menys, V; Chatterjee, A; Colhoun, HM; DeMicco, DA; Deshmukh, HA; Durrington, PN; Ford, I; Fuller, JH; Hitman, GA; Hyde, C; Johnson, T; Jukema, JW; Livingstone, S; McKeigue, PM; Neil, A; Postmus, I; Poulter, N; Sever, P; Shields, DC; Stanton, AV; Trompet, S | 1 |
| Araki, A; Iimuro, S; Ito, H; Matsuyama, Y; Ohashi, Y; Sakurai, T; Shinozaki, T; Umegaki, H | 1 |
| Bragagnolo, JC; Catalano, H; Comignani, PD; Cornejo Pucci, E; Herrera, L; Igarzabal, C; Laffaye, N; Macchia, A; Mariani, JA; Nicolucci, A; Scazziota, AS; Tognoni, G | 1 |
| Hitman, GA | 1 |
| Scheen, AJ | 1 |
| Alavi, KH; Assadi, AR; Damavandi, M; Shafiee, K; Zangiabadi, N | 1 |
| El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A | 1 |
| Cho, HJ; Kim, HS; Kim, SJ; Kwon, YW; Lee, HY; Lee, SW; Oh, BH; Park, YB; Youn, SW | 1 |
| Fromm, MF; Klatt, S; König, J | 1 |
| Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Fujimoto, M; He, P; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Yokote, K | 1 |
| Davies, RR; Durrington, P; Gibson, JM; Gittins, M; Hudson, JE; Narayanan, RP; Oliver, RL; Rutter, MK; Siddals, KW; White, A | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Velussi, M | 1 |
| Biswas, N; Brunzell, JD; Cohen, BR; Freed, MI; Kreider, MM; Marcovina, SM; Ratner, R | 1 |
| Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; van de Ree, MA | 1 |
| Berk-Planken, II; Bootsma, AH; Hoogerbrugge, N; Jansen, H; Stolk, RP | 1 |
| Calzoni, F; Dalla Nora, E; Fellin, R; Passaro, A; Solini, A; Zamboni, PF | 1 |
| Banga, JD; Dallinga-Thie, GM; Erkelens, DW; Sijmonsma, TP; Stolk, RP; van Tol, A; van Venrooij, FV | 1 |
| Charbonnel, B; Krempf, M; Laouenan, H; Magot, T; Marchini, JS; Ouguerram, K; Zaïr, Y | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Julier, K; Mackness, MI; Neil, HA; Soedamah-Muthu, SS; Thomason, MJ | 1 |
| Bonet, R; Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM | 1 |
| De Maat, MP; Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; Van De Ree, MA | 1 |
| Akhmedzhanov, NM; Metel'kaya, VA; Oganov, RG; Raszzivin, VA; Vasiutina, EI | 1 |
| CarloTonolo, G; Carrozza, C; Lulli, P; Musumeci, S; Santini, SA; Zuppi, C | 1 |
| Gylling, H; Miettinen, TA | 1 |
| García-Idoate, G; Mora, C; Muros, M; Navarro, JF | 1 |
| Caselli, A; Economides, PA; Horton, ES; Khaodhiar, L; Tiani, E; Veves, A | 1 |
| Bhansali, A; Gupta, A; Gupta, V; Thapar, S | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Lawrence, JM; Reckless, JP; Reid, J; Stirling, C; Taylor, GJ | 1 |
| Berk-Planken, II; Bootsma, AH; Dallinga-Thie, GM; Jansen, H | 1 |
| Dugi, KA; Hamann, A; Nawroth, PP; Parhofer, KG; Schiekofer, S; Schneider, JG; Volkmer, JE; von Eynatten, M | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Mackness, MI; Neil, HA; Thomason, MJ | 1 |
| Fan, Q; Huang, K; Li, R; Liu, X; Tu, L; Yao, H | 1 |
| Asmus, HG; Krämer, W; Krane, V; Kühn, KW; Kütemeyer, H; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Bagg, W; Braatvedt, GD; Davidson, J; Gamble, G; Reid, IR | 1 |
| Chan, WB; Chow, CC; Ko, GT; Ma, RC; Osaki, R; So, WY; Yeung, VT | 1 |
| Economides, PA; Horton, ES; Mantzoros, CS; Shetty, GK; Veves, A | 1 |
| Bláha, V; Haas, T; Hyspler, R; Smahelová, A; Tichá, A; Zadák, Z | 1 |
| Alcaraz Tafalla, MS; Carrillo Alcaraz, A; Illán Gómez, F; Pascual Díaz, M | 1 |
| Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM | 1 |
| Bern, VH | 1 |
| Croom, KF; Plosker, GL | 1 |
| Endo, K; Ito, Y; Koide, N; Miyashita, Y; Otsuka, M; Oyama, T; Ozaki, H; Saiki, A; Shirai, K | 1 |
| Griebenow, R | 1 |
| Owen, OG | 1 |
| Bierhaus, A; Dugi, KA; Hadziselimovic, S; Hamann, A; Nawroth, PP; Schneider, JG; von Eynatten, M | 1 |
| Eisenbarth, GS | 1 |
| Lee, JD; Mikhailidis, DP; Morrissey, JR; Patel, V | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Assaloni, R; Ceriello, A; Da Ros, R; Esposito, K; Giugliano, D; Maier, A; Piconi, L; Quagliaro, L | 1 |
| Franken, AA; Vincent, HH; Wolffenbuttel, BH | 1 |
| Kakuta, H; Kihara, R; Shimano, H; Suzuki, M; Tada-Iida, K; Takahashi, A; Yamada, N; Yokoo, T | 1 |
| Jarernsiripornkul, N; Kiatchusakul, S; Ojongpian, S; Srinakarin, J; Tantikosoom, W; Thinkhamrop, B | 1 |
| Moreno Sánchez, D | 1 |
| Fantus, IG; Lewis, GF; Stavar, L; Szeto, L; Uffelman, K; Wang, CH; Wong, V | 1 |
| Hirose, T; Kawamori, R; Ohmura, C; Tanaka, Y; Watada, H | 1 |
| Bach-Ngohou, K; Bard, JM; Frénais, R; Krempf, M; Maugère, P; Ouguerram, K; Ripolles-Piquer, B; Zaïr, Y | 1 |
| Krane, V; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Aso, Y; Inukai, T; Inukai, Y; Matsumoto, S; Matsutomo, R; Takebayashi, K; Wakabayashi, S | 1 |
| Emoto, M; Fujiwara, S; Fukumoto, S; Hatsuda, S; Kimoto, E; Koyama, H; Maeno, T; Nishizawa, Y; Shinohara, K; Shoji, T; Yokoyama, H | 1 |
| Tseng, KH | 1 |
| Fujinami, A; Fukui, M; Hasegawa, G; Ichida, Y; Nakamura, N; Nakano, K; Obayashi, H; Ohta, K; Ohta, M; Yoshikawa, T | 1 |
| Berne, C; Jørgensen, L; Sager, P; Siewert-Delle, A; Sorof, J | 1 |
| Langer, A | 1 |
| Robinson, JG | 1 |
| Jaber, BL; Madias, NE | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA; Thomason, MJ | 1 |
| Hobbs, FD | 1 |
| Araki, A; Miyao, M; Sasamoto, K; Yamada, S; Yamanouchi, T; Yanagawa, T | 1 |
| Clearfield, M | 1 |
| Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC | 1 |
| Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M | 1 |
| Lynch, T | 1 |
| Charlton-Menys, V; Durrington, P | 1 |
| Dallinga-Thie, GM; Hattori, H; Rensen, PC; Sijbrands, EJ; van Tol, A | 1 |
| Ishibashi, S; Kusaka, I; Matsuoka, H; Nagasaka, S; Nakata, M; Yada, T | 1 |
| Barter, P; Breazna, A; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, S; Haffner, S; Hsia, J; LaRosa, J; Shepherd, J; Waters, D | 1 |
| Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T | 1 |
| Chu, CH; Chuang, MJ; Keng, HM; Lam, HC; Lee, JK; Lu, CC; Sun, CC; Tai, MH; Wang, MC; Wei, MC | 1 |
| Dallinga-Thie, GM; Hattori, H; Jansen, H; Sijbrands, EJ; van Tol, A; van Vark-van der Zee, LC | 1 |
| Geiss, HC; Huptas, S; Otto, C; Parhofer, KG | 1 |
| d'Emden, M; Knopp, RH; Pocock, SJ; Smilde, JG | 1 |
| Alonso Troncoso, I; Fernández de Bobadilla, J; López de Sa, E; Moreno Gómez, R; Rubio-Terrés, C; Soto Alvarez, J | 1 |
| Plummer, CJ | 1 |
| Cipriano, P; Di Marino, L; Gentile, A; Iovine, C; Lilli, S; Patti, L; Riccardi, G; Rivellese, AA | 1 |
| Krane, V; Wanner, C | 1 |
| Armani, A; Toth, PP | 1 |
| Antoniades, C; Charakida, M; Koniari, K; Kourtellaris, P; Marinou, K; Ntarladimas, I; Siasos, G; Stefanadis, C; Tousoulis, D; Vasiliadou, C | 1 |
| Beddhu, S; Cheung, AK; Kronenberg, F; Kwan, BC | 1 |
| Erkiliç, K; Koç, A; Mistik, S; Ozkiris, A | 1 |
| Andrýs, C; Bláha, M; Bláha, V; Hyspler, R; Knízek, J; Smahelová, A; Solichová, D; Zadák, Z | 1 |
| Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA | 1 |
| Gazi, IF; Mikhailidis, DP | 1 |
| Ferrer-García, JC; Herrera-Ballester, A; Martínez-Mir, I; Pérez-Silvestre, J | 1 |
| Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L | 1 |
| Imaizumi, T; Ishida, S; Jinnouchi, J; Jinnouchi, Y; Takeuchi, M; Yamagishi, S | 1 |
| Moulik, N; Patil, N; Rajadhyaksha, G; Save, V | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; McGuire, A; Neil, HA; Raikou, M | 1 |
| Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M | 1 |
| Betteridge, DJ; Gibson, JM | 1 |
| McMahon, DE | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Abe, M; Hirose, T; Kawamori, R; Mita, T; Nakayama, S; Ogihara, T; Shimizu, T; Uchino, H; Watada, H | 1 |
| Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M | 1 |
| McClendon, KS; Riche, DM | 1 |
| Benatar, JR; Stewart, RA | 1 |
| Betteridge, DJ; Colhoun, H; Durrington, PN; Fuller, J; Hitman, GA; Livingstone, S; Neil, HA; Newman, C; Szarek, M | 1 |
| Arca, M | 1 |
| Betteridge, DJ; Gibson, JM; Sager, PT | 1 |
| Brunetti, ND; Casavecchia, GP; De Gennaro, L; Di Biase, M; Distaso, C; Maulucci, G; Pellegrino, PL | 1 |
| Lyseng-Williamson, KA; Plosker, GL | 1 |
| Bergeron, J; Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Caulin-Glaser, T; Falko, JM; Meis, SB; Moser, RJ | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Dupliakov, DV | 1 |
| Chu, CH; Chuang, MJ; Lam, HC; Lee, JK; Lu, CC; Sun, CC; Wang, MC; Wei, MC | 1 |
| Clarke, LD; Johnson, SJ; Liu, LZ; Ramsey, SD; Roberts, CS; Sullivan, SD | 1 |
| Akalin, A; Akcar, N; Sensoy, B; Temiz, G | 1 |
| Gänzer, H; Kirchmair, R; Patsch, JR; Sturm, W | 1 |
| Krane, V; März, W; Ritz, E; Ruf, G; Wanner, C | 1 |
| Barbagallo, M; Barbieri, M; Giordano, M; Paolisso, G; Petrella, G; Ragno, E; Varricchio, M | 1 |
| Cernigoi, AM; Merni, M; Tortul, C; Velussi, M | 1 |
| Aguilar-Salinas, CA; Alvarado Vega, A; Angélica Gómez-Díaz, R; Eduardo Romero-Nava, L; Gómez-Pérez, FJ; Guillén, LE; Gulías-Herrero, A; Meaney, E; Mendoza Pérez, E; Moguel, R; Novoa, G; Posadas-Romero, C; Salinas-Orozco, S; Vázquez-Chávez, C | 1 |
| Armitage, J; Betteridge, DJ; Colhoun, H | 1 |
| Frost, RJ; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Goldner, D; Insull, W; Kafonek, S; Zieve, F | 1 |
| Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Milionis, HJ | 1 |
| Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Lemmens, PJ; Oranje, WA; Rondas-Colbers, GJ; Sels, JP; Wolffenbuttel, BH | 1 |
| Akanuma, Y; Kawakami, M; Ohashi, Y; Saito, Y; Tanaka, A; Yamada, N | 1 |
| Erkelens, DW | 1 |
| Ai, VH; Chow, WS; Lam, CH; Lam, KS; Tam, SC; Tan, KC | 1 |
| Adeli, K; Cheung, RC; Parris, W; Pontrelli, L | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Mackness, MI; Maton, SM; Neil, HA; Thomason, MJ | 1 |
| de Koning, EJ; Gaillard, CA; Honing, ML; Rabelink, TJ; Stroes, ES; van Etten, RW | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Banga, JD; Bots, ML; Huisman, MV; Stolk, RP; van de Ree, MA; van Venrooij, FV | 1 |
21 review(s) available for atorvastatin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihypertensive Agents; Antimalarials; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Mebendazole; Metformin; Mevalonic Acid; Propranolol; Protein Kinases; Proto-Oncogene Proteins B-raf; Receptors, Adrenergic, beta-2; Tyrosine | 2022 |
Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: a meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; Triglycerides | 2014 |
Atorvastatin Treatment for Carotid Intima-Media Thickness in Chinese Patients With Type 2 Diabetes: A Meta-Analysis.
Topics: Atorvastatin; Carotid Intima-Media Thickness; China; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Morbidity | 2015 |
Topics: Aged; Atorvastatin; Autoantibodies; Diabetes Mellitus, Type 2; Diagnosis, Differential; Disability Evaluation; Humans; Hydroxymethylglutaryl CoA Reductases; Male; Muscle Weakness; Muscular Diseases | 2017 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Rheumatoid arthritis: is it a coronary heart disease equivalent?
Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Pyrroles; Risk Factors | 2011 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Models, Biological; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides | 2006 |
Apolipoproteins AI and B as therapeutic targets.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Lipoproteins; Lipoproteins, LDL; Postprandial Period; Pyrroles | 2006 |
What's in the CARDS?
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Smoking | 2006 |
Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Is it time to stop treating dyslipidaemia with fibrates?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke | 2007 |
Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2007 |
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Heptanoic Acids; Humans; Metabolic Syndrome; Niacin; Pyrroles; Triglycerides; United States | 2005 |
[Clopidogrel and statins or once more on the danger of direct transfer of results of experimental studies in clinical practice].
Topics: Atorvastatin; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2008 |
[Statins in diabetic hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles; Risk Factors; Triglycerides | 1999 |
183 trial(s) available for atorvastatin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Co-Administration of Vitamin E and Atorvastatin Improves Insulin Sensitivity and Peroxisome Proliferator-Activated Receptor-γ Expression in Type 2 Diabetic Patients: A Randomized Double-Blind Clinical Trial.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Insulin Resistance; Leukocytes, Mononuclear; PPAR gamma; Vitamin E | 2022 |
Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus.
Topics: Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2022 |
Impact of atorvastatin reload on the prevention of contrast-induced nephropathy in patients on chronic statin therapy: A prospective randomized trial.
Topics: Atorvastatin; Biomarkers; Contrast Media; Coronary Angiography; Creatinine; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Percutaneous Coronary Intervention; Prospective Studies; Treatment Outcome | 2023 |
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proteins; Quinazolinones; Renal Insufficiency, Chronic; Renin-Angiotensin System; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2019 |
Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Diabetes Mellitus, Type 2; Drug Monitoring; Ezetimibe; Female; Humans; Male; Plaque, Atherosclerotic; Treatment Outcome; Ultrasonography, Interventional | 2021 |
Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning.
Topics: Adult; Atorvastatin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Fatty Acids, Omega-3; Female; Fish Oils; Health Care Costs; Humans; Male; Quality-Adjusted Life Years; Risk Reduction Behavior | 2020 |
Forty-eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Femur; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lower Extremity; Male; Middle Aged; Plaque, Atherosclerotic; Quinolines; Treatment Outcome | 2021 |
Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia.
Topics: Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Egypt; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Inflammation Mediators; Lipids; Male; Middle Aged; Prospective Studies; Rosuvastatin Calcium; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2021 |
A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Dialysis | 2021 |
[IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME].
Topics: Acute Coronary Syndrome; Aspirin; Atorvastatin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Drug Interactions; Drug Substitution; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Rosuvastatin Calcium; Ticlopidine | 2017 |
Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; China; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Plaque, Atherosclerotic | 2017 |
Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Life Style; Lipids; Male; Middle Aged; Prospective Studies; Rosuvastatin Calcium; Thyroid Function Tests; Thyroid Gland; Thyroid Nodule | 2018 |
Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials.
Topics: Atorvastatin; Cholesterol; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Function Tests; Male; Middle Aged; Proteinuria; Rosuvastatin Calcium | 2019 |
Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects.
Topics: Adult; Atorvastatin; Benzamides; Cross-Over Studies; Cyclopropanes; Diabetes Mellitus, Type 2; Drug Interactions; Female; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Japan; Male; Middle Aged; Oxadiazoles; Receptors, G-Protein-Coupled; Rosuvastatin Calcium | 2019 |
Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Republic of Korea; Simvastatin; Treatment Outcome | 2013 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Triglycerides | 2013 |
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRES
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Patient Safety; Phenylpropionates; Prospective Studies; Pyrroles; Risk Reduction Behavior; Treatment Failure; Treatment Outcome; Triglycerides | 2014 |
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors | 2014 |
Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
Topics: Aged; Arginine Vasopressin; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Natriuretic Peptide, Brain; Nitric Oxide; omega-N-Methylarginine; Pulse Wave Analysis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Vascular Stiffness; Vasopressins | 2014 |
The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matrix Metalloproteinase 7; Matrix Metalloproteinase 8; Middle Aged; Pyrroles | 2014 |
LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes.
Topics: Adult; Age of Onset; Aged; Anticholesteremic Agents; Atorvastatin; Autoantibodies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucose Intolerance; Glutamate Decarboxylase; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Phenotype; Prevalence; Prospective Studies; Pyrroles; Risk Factors | 2014 |
Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Middle Aged; Pilot Projects; Pyrroles; Quality of Life | 2014 |
Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelial Progenitor Cells; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Germany; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins, HDL; Male; Middle Aged; Proportional Hazards Models; Pulmonary Surfactant-Associated Protein B; Pyrroles; Renal Dialysis; Risk Factors; Serum Amyloid A Protein; Time Factors; Treatment Outcome | 2015 |
Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
Topics: Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Incidence; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sex Factors | 2015 |
No effects of atorvastatin (10 mg/d or 80 mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Atorvastatin; Creatinine; Diabetes Mellitus, Type 2; Dinoprost; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Prostaglandins I; Thromboxanes | 2015 |
Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Cause of Death; Cholesterol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Renal Dialysis; Risk Factors; Serum Albumin; Survival Rate; Troponin T; Uremia | 2015 |
Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; China; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2015 |
Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged | 2015 |
A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Ezetimibe; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pilot Projects; Triglycerides | 2015 |
The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteoprotegerin; Pulse Wave Analysis; Treatment Outcome; Vascular Stiffness | 2015 |
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid | 2015 |
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds | 2016 |
Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Female; Glycated Hemoglobin; Humans; Ireland; Male; Middle Aged; United Kingdom | 2016 |
Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Down-Regulation; Drug Substitution; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Rosuvastatin Calcium; Treatment Outcome | 2016 |
Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoprotein(a); Atorvastatin; Biomarkers; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipoprotein(a); Male; Middle Aged; Phenotype; Prospective Studies; Protein Isoforms; Renal Dialysis; Survival Rate; Time Factors; Young Adult | 2016 |
Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Surveys and Questionnaires; Time Factors | 2016 |
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering
Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Myocardial Infarction; North America; Predictive Value of Tests; Protective Factors; Reproducibility of Results; Risk Assessment; Risk Factors; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome; United Kingdom | 2016 |
Efficacy of Subgingivally Delivered 1.2% Atorvastatin in the Treatment of Chronic Periodontitis in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial.
Topics: Alveolar Bone Loss; Anti-Bacterial Agents; Atorvastatin; Chronic Periodontitis; Dental Scaling; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Periodontal Index; Root Planing | 2016 |
Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long Term Adverse Effects; Male; Middle Aged; Percutaneous Coronary Intervention; Prognosis; Proportional Hazards Models; Treatment Outcome | 2016 |
The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: A cluster randomi
Topics: Aged; Atorvastatin; Behavior Therapy; Case-Control Studies; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Early Intervention, Educational; Female; Health Promotion; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Motivation; Risk Reduction Behavior; United Kingdom | 2016 |
Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.
Topics: Aged; Albuminuria; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; Male; Membrane Proteins; Middle Aged; Pilot Projects; Podocytes; Prospective Studies; Rosuvastatin Calcium; Vascular Endothelial Growth Factor A | 2017 |
Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Atorvastatin; Biomarkers; Blood Glucose; Cholesterol; Curcumin; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Pyrroles; Triglycerides | 2008 |
Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Feasibility Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2008 |
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk; Treatment Outcome; United States | 2008 |
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Male; Middle Aged; Muscular Diseases; Practice Guidelines as Topic; Pyrroles; Time Factors; Treatment Outcome; United Kingdom | 2008 |
Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Protein Multimerization; Pyrroles | 2009 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cause of Death; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Inflammation; Middle Aged; Placebos; Predictive Value of Tests; Pyrroles; Renal Dialysis; Survival Rate; Treatment Outcome; Young Adult | 2008 |
How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
Topics: Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2008 |
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Triglycerides | 2009 |
Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycemic Index; Heptanoic Acids; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Pyrroles | 2008 |
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Body Size; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Placebos; Pyrroles | 2009 |
Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Atorvastatin; Blood Flow Velocity; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Pyrroles; Vasodilation; Young Adult | 2008 |
Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2009 |
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis.
Topics: Aged; Arrhythmias, Cardiac; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Practice Guidelines as Topic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2009 |
Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.
Topics: Adiponectin; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Pyrroles | 2009 |
Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors | 2010 |
[Comparison of the effects of carbohydrate metabolism compensation and atorvastatin treatment on lipid metabolism and C-reactive protein in type 2 diabetes mellitus].
Topics: Atorvastatin; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Male; Middle Aged; Pyrroles | 2008 |
Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients.
Topics: Acute-Phase Proteins; Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Ferritins; Fibrinogen; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors | 2009 |
Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein.
Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Heptanoic Acids; High-Density Lipoproteins, Pre-beta; Humans; Male; Middle Aged; Phospholipid Transfer Proteins; Pyrroles; Triglycerides | 2009 |
Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2009 |
Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes.
Topics: Adult; Aged; Ankle; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Flow Velocity; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pulsatile Flow; Pyrroles; Treatment Outcome | 2008 |
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult | 2009 |
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Aged; Albuminuria; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2009 |
Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).
Topics: Atherosclerosis; Atorvastatin; Diabetes Mellitus, Type 2; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Outcome | 2009 |
Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Inflammation; Male; Prospective Studies; Pyrroles; Renal Dialysis | 2009 |
A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study).
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cross-Over Studies; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Drug Administration Schedule; Estradiol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydrocortisone; Luminescent Measurements; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric; Testosterone; Treatment Outcome | 2009 |
Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides | 2010 |
Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Peptide Hormones; Pyrroles; Sodium | 2010 |
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Black People; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2010 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Diseases; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Factor 4; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
Efficacy of low dose atorvastatin in diabetic dyslipidaemia.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; France; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Time Factors; Treatment Outcome; Triglycerides; Up-Regulation | 2010 |
Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2010 |
Low-dose statin therapy improves endothelial function in type 2 diabetic patients with normal serum total cholesterol: a randomized placebo-controlled study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Cholesterol; Diabetes Mellitus, Type 2; Endothelium, Vascular; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Pyrroles; Statistics, Nonparametric; Time Factors | 2010 |
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Lanosterol; Phytosterols; Pyrroles; Triglycerides | 2010 |
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
Topics: Albuminuria; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome; United Kingdom | 2011 |
Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.
Topics: Atherosclerosis; Atorvastatin; Blood Flow Velocity; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Plethysmography; Pyrroles; Single-Blind Method; Treatment Outcome; Vasodilation | 2010 |
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome | 2011 |
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Biomarkers; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glycopeptides; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Predictive Value of Tests; Pyrroles; Regression Analysis; Risk Factors; Stroke; Treatment Outcome | 2011 |
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Atorvastatin; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fibric Acids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phospholipases A2; Phospholipases A2, Secretory; Pyrroles | 2011 |
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pyrroles; Risk Factors | 2011 |
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients.
Topics: Adolescent; Adult; Aged; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oxidative Stress; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult | 2011 |
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Physiological Phenomena; Cholesterol; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Stroke; Triglycerides; Young Adult | 2011 |
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2011 |
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Young Adult | 2011 |
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivale
Topics: Adult; Asian People; Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrroles; Therapeutic Equivalency; Vital Signs; Young Adult | 2011 |
Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
Topics: Acetates; Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-6; Keto Acids; Male; Middle Aged; Pyrroles; Treatment Outcome | 2011 |
Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glucose Intolerance; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Oxidation-Reduction; Prospective Studies; Pyrroles | 2012 |
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study.
Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Fasting; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2012 |
Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Area Under Curve; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Renal Dialysis; Risk Factors | 2012 |
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Thrombin | 2012 |
Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Electrophysiology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neural Conduction; Pyrroles; Rats; Tibial Nerve | 2012 |
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke | 2013 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Atorvastatin administration is associated with dose-related changes in IGF bioavailability.
Topics: Aged; Atorvastatin; Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Male; Middle Aged; Pyrroles | 2013 |
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; North America; Pyrroles; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome | 2002 |
Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant.
Topics: Aged; Alleles; Atorvastatin; Black People; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Genetic Variation; Heptanoic Acids; Heterozygote; Humans; Hyperlipidemias; Lipase; Liver; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Sex Characteristics; White People | 2003 |
Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cadherins; Cholesterol, LDL; Diabetes Mellitus, Type 2; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2003 |
Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
Topics: Aged; Atorvastatin; Base Sequence; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Diabetes Mellitus, Type 2; DNA Primers; Double-Blind Method; Female; Genotype; Glycated Hemoglobin; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Placebos; Polymorphism, Genetic; Pyrroles; Restriction Mapping; Triglycerides | 2003 |
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Myocardial Ischemia; Patient Compliance; Probability; Pyrroles; Reference Values; Risk Assessment; Treatment Outcome | 2003 |
Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Gemfibrozil; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Factor VIIIa; Female; Fibrinogen; Hemostatics; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Placebos; Pyrroles; Risk Factors; Time Factors; Tissue Plasminogen Activator; von Willebrand Factor | 2003 |
Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Gonadal Steroid Hormones; Gonads; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Severity of Illness Index | 2003 |
The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes.
Topics: Adult; Atorvastatin; Biomarkers; Brachial Artery; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Microcirculation; Middle Aged; Nitroglycerin; Pyrroles; Regional Blood Flow; Risk Factors; Skin; Vasodilation; Vasodilator Agents | 2004 |
Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema.
Topics: Administration, Oral; Atorvastatin; Chemotherapy, Adjuvant; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Exudates and Transudates; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Laser Coagulation; Lipoproteins, LDL; Macular Edema; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides; Visual Acuity | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Apolipoproteins B; Atorvastatin; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Reference Values; Treatment Outcome | 2004 |
Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
Topics: Angiotensin-Converting Enzyme Inhibitors; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypertriglyceridemia; Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo.
Topics: Aged; Atorvastatin; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipoprotein Lipase; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis | 2004 |
The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes.
Topics: Atorvastatin; Biomarkers; Bone Remodeling; Confidence Intervals; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Osteocalcin; Pyrroles | 2004 |
A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2004 |
Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.
Topics: Adiponectin; Adult; Age Distribution; Aged; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Hormones, Ectopic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Prediabetic State; Predictive Value of Tests; Probability; Prognosis; Pyrroles; Reference Values; Resistin; Risk Assessment; Sex Distribution; Vascular Resistance | 2004 |
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein Lipase; Middle Aged; Pravastatin; Pyrroles | 2004 |
The collaborative atorvastatin diabetes study: preliminary results.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Prospective Studies; Pyrroles | 2005 |
Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes.
Topics: Adiponectin; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Hormones, Ectopic; Humans; Intercellular Signaling Peptides and Proteins; Leptin; Male; Placebos; Pyrroles; Resistin | 2005 |
Statin treatment of patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke | 2005 |
Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Biphenyl Compounds; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperglycemia; Hypertriglyceridemia; Inflammation; Irbesartan; Male; Middle Aged; Oxidative Stress; Postprandial Period; Pyrroles; Tetrazoles; Treatment Outcome | 2005 |
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2005 |
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Pyrroles; Vascular Diseases | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Renal Dialysis; Stroke | 2005 |
The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus, Type 2; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles | 2005 |
Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Atorvastatin; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mice; Middle Aged; Monocytes; Pyrroles; Resistin; RNA, Messenger | 2006 |
Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients.
Topics: Aged; Albuminuria; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Proportional Hazards Models; Pyrroles; Risk Factors; Time Factors; Treatment Outcome | 2005 |
Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients.
Topics: Adult; Atorvastatin; Biomarkers; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Japan; Liver; Liver Function Tests; Male; Middle Aged; Pyrroles | 2006 |
Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides; Vasodilator Agents | 2006 |
Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers; Deoxyguanosine; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidative Stress; Probucol; Pyrroles; Treatment Outcome | 2006 |
Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E?
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins E; Atorvastatin; Cholesterol; Diabetes Mellitus, Type 2; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Phospholipid Transfer Proteins; Placebos; Pyrroles | 2006 |
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Topics: Aged; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides | 2006 |
The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyslipidemias; Endothelin-1; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2006 |
Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.
Topics: Aged; Apolipoprotein A-V; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins E; Atorvastatin; Diabetes Complications; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genetic Variation; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Placebos; Pyrroles; Triglycerides | 2006 |
Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
Topics: Adult; Atorvastatin; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Pyrroles; Treatment Outcome | 2006 |
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2006 |
Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Lessons learnt from the 4D trial.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Placebos; Pyrroles; Renal Dialysis | 2006 |
The CARDS trial: diabetic patients dealt a winning hand.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome | 2006 |
Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus.
Topics: Anti-Inflammatory Agents; Antioxidants; Arginine; Ascorbic Acid; Atorvastatin; Cytokines; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hyperemia; Male; Middle Aged; Pyrroles; Regional Blood Flow; Single-Blind Method; Vitamins | 2007 |
Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy.
Topics: Atorvastatin; Blood Flow Velocity; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Eye; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Ophthalmic Artery; Pyrroles; Retinal Artery; Triglycerides | 2007 |
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Age Distribution; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Risk Reduction Behavior; Stroke | 2006 |
Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Spain | 2006 |
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matched-Pair Analysis; Pyrroles | 2006 |
Effect of atorvastatin on type 2 diabetic dyslipidemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Superoxide Dismutase; Time Factors; Treatment Outcome; Triglycerides | 2006 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin | 2006 |
Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia.
Topics: Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hypercholesterolemia; Insulin-Secreting Cells; Japan; Patient Compliance; Pravastatin; Pyrroles | 2007 |
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Topics: Adiponectin; Aged; Atorvastatin; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Ghrelin; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Peptide Hormones; Pyrroles; Resistin | 2007 |
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2007 |
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; England; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North Carolina; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.
Topics: Aged; Atorvastatin; C-Reactive Protein; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2007 |
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Atorvastatin; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypertriglyceridemia; Kinetics; Leucine; Male; Middle Aged; Pyrroles; Triglycerides | 2008 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles | 2008 |
Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Leptin; Male; Middle Aged; Pyrroles | 2008 |
Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Regional Blood Flow; Time Factors; Treatment Outcome | 2008 |
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Topics: Aged; Atorvastatin; Calorimetry, Indirect; Carbon Dioxide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Oxygen Consumption; Pyrroles; Simvastatin; Single-Blind Method; Triglycerides | 2000 |
Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 1999 |
Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles | 2000 |
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric | 2001 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Placebos; Pyrroles; Time Factors; Triglycerides | 2001 |
Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Atorvastatin; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidation-Reduction; Pyrroles; Ubiquinone; Vitamin E | 2001 |
A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2001 |
Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Reference Values; Triglycerides; Ultrasonography; Vasodilation | 2002 |
Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Topics: Apolipoproteins B; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Peptide Fragments; Pyrroles | 2002 |
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Lipids; Lipoproteins; Middle Aged; Patient Selection; Placebos; Pyrroles; Research Design | 2002 |
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides | 2002 |
Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Lipids; Male; Middle Aged; Placebos; Pyrroles; Smoking; Vasodilation | 2002 |
135 other study(ies) available for atorvastatin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report.
Topics: Atorvastatin; Bezafibrate; Deafness; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Lipoprotein Lipase; Mitochondrial Diseases; Mutation | 2022 |
COMPARISON OF REAL WORLD LIPID PROFILE OF PATIENTS WITH TYPE 2 DIABETES AND GUIDELINE RECOMMENDATIONS.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Risk Factors | 2021 |
Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Atorvastatin; Case-Control Studies; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Interleukin-10; Interleukin-12; Leukocytes, Mononuclear; Models, Biological; Vascular Endothelial Growth Factor A | 2021 |
The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model.
Topics: Animals; Atorvastatin; Benzhydryl Compounds; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Liraglutide; Male; Pyrroles; Rats; Thyrotropin | 2022 |
Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank.
Topics: Atorvastatin; Biological Specimen Banks; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glycemic Control; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Simvastatin; United Kingdom | 2022 |
Effects of Ethanolic Extract of
Topics: Animals; Atorvastatin; Chromatography, Liquid; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Schisandra; Simvastatin; Tandem Mass Spectrometry | 2022 |
Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide.
Topics: Acetaminophen; Atorvastatin; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents | 2022 |
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Perindopril | 2022 |
Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients.
Topics: Atorvastatin; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Humans; Metformin; Percutaneous Coronary Intervention; Risk Factors; Sirolimus; Stents; Treatment Outcome | 2022 |
The Role of Preoperative Chronic Statin Therapy in Heart Transplant Receipts-A Retrospective Single-Center Cohort Study.
Topics: Acute Kidney Injury; Atorvastatin; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postoperative Complications; Retrospective Studies | 2023 |
[Lipid-lowering Eeficacy and Safety of High Doses of Atorvastatin and Rosuvastatin].
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Retrospective Studies; Rosuvastatin Calcium; Triglycerides | 2023 |
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |
Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Simvastatin; Stroke; Treatment Outcome | 2023 |
Protective effects of statins on the incidence of NAFLD-related decompensated cirrhosis in T2DM.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Non-alcoholic Fatty Liver Disease; Risk Factors | 2023 |
Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment.
Topics: Aged; Atorvastatin; Bilirubin; Diabetes Mellitus, Type 2; Ezetimibe; Glucose; Humans; Hypertension | 2023 |
[Can a lipophilic statin improve the treatment of heart failure with preserved ejection fraction in patients with hypertension and obesity?]
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Obesity; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2023 |
Atorvastatin Inhibited ROS Generation and Increased IL-1β And IL-6 Release by Mononuclear Cells from Diabetic Patients.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Interleukin-6; Leukocytes, Mononuclear; Male; Middle Aged; NADPH Oxidases; Protein Kinase C beta; Reactive Oxygen Species; Secretory Pathway | 2019 |
Interactions between Atorvastatin and the Farnesoid X Receptor Impair Insulinotropic Effects of Bile Acids and Modulate Diabetogenic Risk.
Topics: Animals; Atorvastatin; Bile Acids and Salts; Cells, Cultured; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; Risk Factors | 2020 |
Pale retinal vessels in newly diagnosed type 2 diabetes.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Retinal Vessels | 2020 |
The Influence of Endothelial Nitric Oxide Synthase (eNOS) Genetic Polymorphisms on Cholesterol Blood Levels Among Type 2 Diabetic Patients on Atorvastatin Therapy.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Young Adult | 2021 |
Immune-mediated necrotising myopathy is a rare statin-associated adverse effect: a case report.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Gliclazide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Middle Aged; Myotoxicity; Vildagliptin | 2020 |
The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Hypercholesterolemia; Hyperlipidemias; Inflammation; Male; Metabolic Syndrome; Oxidative Stress; Rats; Silymarin; Triglycerides | 2021 |
Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice.
Topics: Animals; Aspalathus; Atorvastatin; Blood Glucose; Chalcones; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Phytotherapy; Pioglitazone; Plant Extracts | 2021 |
Mediational g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin's effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Humans | 2021 |
Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus.
Topics: Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; HMGB Proteins; HMGB1 Protein; Humans; Myocardial Infarction; Prospective Studies | 2021 |
Characteristics of carotid atherosclerosis in elderly patients with type 2 diabetes at different disease course, and the intervention by statins in very elderly patients.
Topics: Aged; Aged, 80 and over; Atorvastatin; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Male; Treatment Outcome | 2018 |
[Atorvastatin therapy under clinical practice conditions - which LDL-C levels are achieved in patients at very high cardiovascular risk?]
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Risk | 2017 |
More on carotid atherosclerosis and ezetimibe.
Topics: Atorvastatin; Carotid Artery Diseases; Carotid Stenosis; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans | 2017 |
Apoptosis in pancreatic β-cells is induced by arsenic and atorvastatin in Wistar rats with diabetes mellitus type 2.
Topics: Animals; Antioxidants; Apoptosis; Arsenic; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Secreting Cells; Male; Rats, Inbred WKY; Streptozocin | 2018 |
Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Controlled Before-After Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mexico; Middle Aged; THP-1 Cells; Time Factors; Treatment Outcome; Young Adult | 2018 |
Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pulse Wave Analysis; Risk Factors; Time Factors; Treatment Outcome; Vascular Stiffness | 2019 |
Apelin‑13 ameliorates metabolic and cardiovascular disorders in a rat model of type 2 diabetes with a high‑fat diet.
Topics: Animals; Atorvastatin; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Heart Function Tests; Hemodynamics; Intercellular Signaling Peptides and Proteins; Lipid Metabolism; Male; Metformin; Oxidation-Reduction; Protective Agents; Rats | 2018 |
Hyperfibrinogenemia in Peripheral Arterial Disease: Coexistent and Independent Risk Factor (A Report of Two Cases and Review of Literature).
Topics: Amputation, Surgical; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Fibrinogen; Humans; Hypolipidemic Agents; Intermittent Claudication; Ischemia; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Predictive Value of Tests; Risk Factors; Treatment Outcome | 2018 |
Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lipids; Male; Middle Aged; Myocardium | 2019 |
[Toxic myopathy associated with concomitant treatment with atorvastatin and colchicine].
Topics: Aged; Arthritis, Gouty; Atorvastatin; Biopsy; Colchicine; Diabetes Mellitus, Type 2; Drug Synergism; Dyslipidemias; Electromyography; Humans; Kidney Failure, Chronic; Male; Muscle, Skeletal; Muscular Diseases; Quadriplegia | 2019 |
Comparison of metabolic profile of obese non-diabetic patients with coronary artery disease depending on atorvastatin dose.
Topics: Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Metabolome; Obesity; Ukraine | 2019 |
Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ethiopia; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2019 |
Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Time Factors; Ultrasonography, Interventional | 2013 |
Standards of statin usage in Poland in high-risk patients: 3ST-POL study results.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Patient Compliance; Poland; Population Surveillance; Primary Health Care; Pyrroles; Simvastatin; Surveys and Questionnaires; Treatment Failure | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Effects of atorvastatin and insulin in vascular dysfunction associated with type 2 diabetes.
Topics: Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Hypoglycemic Agents; Insulin; Male; Pyrroles; Rats; Treatment Outcome | 2014 |
CIDE--A gene expression in patients with abdominal obesity and LDL hyperlipoproteinemia qualified for surgical revascularization in chronic limb ischemia.
Topics: Aged; Apoptosis Regulatory Proteins; Atorvastatin; Body Mass Index; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Humans; Hyperlipoproteinemias; Ischemia; Leg; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal | 2013 |
Mystery case: a 63-year-old man with progressive proximal pain and weakness.
Topics: Atorvastatin; Blood Sedimentation; C-Reactive Protein; Creatine Kinase; Diabetes Mellitus, Type 2; Disease Progression; Electromyography; Fatigue; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Weakness; Neuromuscular Junction Diseases; Pain; Pyrroles; Shoulder Pain; Tomography, X-Ray Computed | 2014 |
Atorvastatin prevents type 2 diabetes mellitus--an experimental study.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Male; Pyrroles; Rats; Rats, Wistar; Triglycerides | 2014 |
LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation.
Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Monitoring; Half-Life; Heptanoic Acids; Humans; Hypolipidemic Agents; Immunoassay; Prospective Studies; Pyrroles; Simvastatin; Triglycerides | 2015 |
The effect of leptin promoter and leptin receptor gene polymorphisms on lipid profile among the diabetic population: modulations by atorvastatin treatment and environmental factors.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gene-Environment Interaction; Genotype; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Receptors, Leptin; Sex Factors; Triglycerides | 2014 |
Statins on trial. Pfizer faces clot of lawsuits that claim Lipitor caused women's diabetes.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Drug Industry; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Sex Factors; United States | 2014 |
[Impacts of atorvastatin on blood lipids and arterial media thickness in new-onset type 2 diabetes patients].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Tunica Media | 2014 |
Vascular injury in diabetic db/db mice is ameliorated by atorvastatin: role of Rac1/2-sensitive Nox-dependent pathways.
Topics: Acetylcholine; Animals; Arteries; Atorvastatin; Blotting, Western; Diabetes Mellitus, Type 2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; In Vitro Techniques; Insulin; Lipids; Male; Mice, Mutant Strains; Mitogen-Activated Protein Kinases; NADPH Oxidases; Phosphorylation; Pyrroles; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RAC2 GTP-Binding Protein; Reactive Oxygen Species; Receptors, Leptin; Signal Transduction; Thiobarbituric Acid Reactive Substances; Vasodilation; Vasodilator Agents | 2015 |
Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Atorvastatin; China; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Taiwan | 2015 |
Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes.
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Glucose; Blood Pressure; Chemokine CCL5; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells; Hypertension; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Peroxynitrous Acid; Rats, Inbred SHR | 2015 |
Ameliorative Effect of Adjunct Therapy of Metformin with Atorvastatin on Streptozotocin-induced Diabetes Mellitus in Rats.
Topics: Animals; Antioxidants; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glutathione; Hypoglycemic Agents; Insulin; Lipid Peroxidation; Lipids; Lipoproteins, HDL; Male; Metformin; Rats; Rats, Wistar; Streptozocin; Triglycerides | 2016 |
Urea and protein carbamylation in ESRD: surrogate markers or partners in crime?
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Serum Albumin | 2015 |
Combining citrulline with atorvastatin preserves glucose homeostasis in a murine model of diet-induced obesity.
Topics: AMP-Activated Protein Kinases; Animals; Atorvastatin; Cell Line, Tumor; Citrulline; Diabetes Mellitus, Type 2; Diet; Dietary Fats; Dietary Sucrose; Disease Models, Animal; Drug Therapy, Combination; Glucose; Homeostasis; Humans; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Obesity; Sterol Regulatory Element Binding Protein 1 | 2015 |
Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Causality; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Disease Progression; Glucose Intolerance; Glucose Tolerance Test; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Lipids; Liver; Male; Pancreas; Pioglitazone; Postprandial Period; Prediabetic State; Random Allocation; Rats; Rats, Wistar; Thiazolidinediones | 2016 |
The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Topics: Adult; Atorvastatin; Biological Transport; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Female; Gemfibrozil; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged | 2016 |
Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study).
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adiponectin; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; CD40 Ligand; Chemokine CCL2; Coronary Artery Disease; Cystatin C; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insulin; Intercellular Adhesion Molecule-1; Lipoprotein(a); Male; Matrix Metalloproteinase 9; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Neopterin; Osteopontin; Peptide Fragments; Peroxidase; Randomized Controlled Trials as Topic; Receptor for Advanced Glycation End Products; Risk Factors; Secondary Prevention; Vascular Cell Adhesion Molecule-1; Vitamin D | 2016 |
Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes.
Topics: Adult; Aged; Animals; Antagomirs; Atorvastatin; Blotting, Northern; Carrier Proteins; Complement Factor H; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycoproteins; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Male; Mass Spectrometry; Metabolic Syndrome; Mice; MicroRNAs; Middle Aged; Multivariate Analysis; Obesity; Oligonucleotides; Prevalence; Prospective Studies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Serum Albumin; Serum Albumin, Human | 2017 |
A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Drug Therapy, Combination; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Lipids; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains | 2009 |
Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies | 2008 |
Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Biological Availability; Diabetes Mellitus, Type 2; Estradiol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Simvastatin; Testosterone | 2009 |
Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles | 2009 |
Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats.
Topics: Acute Disease; Animals; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Diabetes Mellitus, Type 2; Drug Administration Schedule; Heptanoic Acids; Male; Pyrroles; Rats; Rats, Wistar; Time Factors | 2009 |
Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2009 |
Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2009 |
Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes.
Topics: Asian People; Atorvastatin; Cell Line; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2010 |
Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2009 |
Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
Topics: Aged; Atorvastatin; Belgium; Cardiovascular Diseases; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drugs, Generic; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Models, Statistical; Pyrroles; Quality-Adjusted Life Years; Triglycerides | 2010 |
Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; CD36 Antigens; Cells, Cultured; Diabetes Mellitus, Type 2; Down-Regulation; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Monocytes; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Pyrroles; Tumor Necrosis Factor-alpha | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States | 2010 |
Charting new territory by simulated modeling of a clinical trial.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2010 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Atorvastatin prevents ischemic limb loss in type 2 diabetes: role of p53.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Extremities; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Ischemia; Male; Mice; Myoblasts; Peripheral Arterial Disease; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Pyrroles; Tumor Suppressor Protein p53; Ubiquitin; Wound Healing | 2011 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2011 |
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome | 2011 |
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register.
Topics: Adolescent; Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Registries; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Sweden; Treatment Outcome | 2011 |
The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Hypolipidemic Agents; Lipids; Male; Pyrroles; Rats; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
Drug repurposing for vascular protection after acute ischemic stroke.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Brain Infarction; Diabetes Mellitus, Type 2; Disease Models, Animal; Enalapril; Enzyme-Linked Immunosorbent Assay; Functional Laterality; Hemoglobins; Hemorrhage; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Reperfusion; Stroke; Tetrazoles; Vascular System Injuries | 2011 |
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Apelin; Atorvastatin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Female; Ghrelin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Pyrroles | 2012 |
Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Function Tests; Male; Middle Aged; Prognosis; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Triglycerides | 2011 |
Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Genome-Wide Association Study; Genotype; Glucosyltransferases; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebo Effect; Polymorphism, Single Nucleotide; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Lysophosphatidic Acid; Treatment Outcome | 2012 |
Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-pres
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Proportional Hazards Models; Pyrroles | 2012 |
Statins and glycaemic control--a cause for concern?
Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kruppel-like factor 2.
Topics: Animals; Atorvastatin; Base Sequence; Binding Sites; Blood Glucose; Cells, Cultured; Chromatin Immunoprecipitation; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Male; Mevalonic Acid; Molecular Sequence Data; Nerve Tissue Proteins; Nitric Oxide Synthase Type III; Phosphorylation; Promoter Regions, Genetic; Pyrroles; Rats; Rats, Inbred OLETF; RNA Interference; Time Factors; Transfection; Vasodilation; Vasodilator Agents | 2013 |
The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members.
Topics: Administration, Oral; Atorvastatin; Biological Transport; Diabetes Mellitus, Type 2; Drug Interactions; HEK293 Cells; Heptanoic Acids; Humans; Hypoglycemic Agents; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfobromophthalein | 2013 |
Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Podocytes; Pyrroles | 2013 |
The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin; Treatment Outcome; Vitamin D | 2013 |
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides | 2002 |
Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Kinetics; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
[Comparative study of lipid lowering effect and influence on platelet aggregation of atorvastatin and simvastatin in patients ischemic heart disease with type II diabetes and combined hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Pyrroles; Simvastatin | 2003 |
Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Feces; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Absorption; Lipids; Lipoproteins; Liver; Male; Middle Aged; Phytosterols; Pyrroles; Squalene | 2003 |
Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Homocysteine; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Renal Dialysis; Risk Factors | 2003 |
The lipid-regulating effects of atorvastatin on type 2 elder diabetes patients with hyperlipidemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease.
Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Sterols | 2005 |
[Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus].
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2004 |
[CARDS confirms usefulness of LDL lowering in type 2 diabetics].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Placebos; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Time Factors | 2004 |
[The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome | 2005 |
CARDS on the table: should everybody with type 2 diabetes take a statin?
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Vascular Diseases | 2005 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |
Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
Topics: Animals; Arteriosclerosis; Atorvastatin; Biomarkers; Blood Glucose; Blotting, Northern; CCAAT-Enhancer-Binding Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Glucose Tolerance Test; Glucose-6-Phosphatase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred Strains; Pyrroles; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2005 |
Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.
Topics: Adipose Tissue; Animals; Atorvastatin; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Phosphorylation; Pyrroles; Rats; Rats, Zucker | 2006 |
Acute onset and worsening of diabetes concurrent with administration of statins.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles | 2005 |
Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins E; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles | 2005 |
Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus.
Topics: Aged; Arteries; Atorvastatin; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leg; Male; Middle Aged; Prospective Studies; Pyrroles | 2005 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server et al.
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Risk Factors; Stroke | 2005 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2006 |
Medication costs as a primary cause of nonadherence in the elderly.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Prescriptions; Drugs, Generic; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Metoprolol; Patient Compliance; Pharmacists; Pyrroles; Self Administration | 2006 |
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
Topics: 3T3 Cells; Adipocytes; Animals; Atorvastatin; Biological Transport; Blood Glucose; Cell Differentiation; Cellular Senescence; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Glucose Transporter Type 4; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Middle Aged; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies | 2006 |
[Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study].
Topics: Adult; Aged; Atorvastatin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Retrospective Studies | 2006 |
High-dose statins for diabetes.
Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2006 |
Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis | 2006 |
Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover.
Topics: Atorvastatin; CD40 Antigens; Chemokine CCL2; Cholesterol; Diabetes Mellitus, Type 2; E-Selectin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Lipid Metabolism; Lipopolysaccharide Receptors; Male; Middle Aged; P-Selectin; Pyrroles | 2006 |
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles | 2006 |
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.
Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left | 2007 |
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Models, Economic; Primary Prevention; Pyrroles; Quality-Adjusted Life Years | 2007 |
Did a flawed study design affect the results of the VYTAL study?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Random Allocation; Research Design; Simvastatin | 2007 |
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; Pyrroles; Quality-Adjusted Life Years | 2008 |
Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes.
Topics: Atherosclerosis; Atorvastatin; Biomarkers; Brachial Artery; Carotid Arteries; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Tunica Intima | 2008 |
Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Research Design; Treatment Outcome | 1999 |
Status report of lipid-lowering trials in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Risk Factors | 2000 |
Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Pyrroles | 2001 |
Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects.
Topics: Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2001 |
Insulin resistance syndrome and type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Metabolic Syndrome; Pyrroles; Risk Factors; Survival Rate | 2001 |
Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Microcirculation; Middle Aged; Nitric Oxide; Nitroprusside; Plethysmography; Prospective Studies; Pyrroles; Serotonin; Vasodilation | 2002 |